Chronic News and Research

RSS

Obama administration plans 'stealth' study of patient access to physicians

In an effort to explore what the administration termed a "critical public policy problem" — a shortage of primary care physicians — a team of "mystery shoppers" will be recruited to find out how hard it is to get care when it is needed.

27 Jun 2011

Viewpoints: Supreme Court drug decisions; Medicaid's burden; Concierge medicine questioned

The image of Justice blindfolded, holding her scales, is familiar from courthouses all over the United States and the world. Sadly, in its Thursday ruling in the case of PLIVA v Mensing, the U.S. Supreme Court made a decision that makes one wonder if that blindfold made the court unable to see the right thing to do.

27 Jun 2011

Researchers identify how sooty mangabeys survive SIV infection

Sooty mangabeys, a type of African monkey, have intrigued scientists for years because they can survive infection by SIV, a relative of HIV, and not succumb to AIDS.

27 Jun 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

First Edition: June 27, 2011

Today's headlines include reports about the status of ongoing deficit negotiations and details about a "stealth" survey on access to doctors.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable system for severe headaches, today announced positive preliminary findings from a study evaluating the safety and efficacy of the company's investigational neurostimulation system for the treatment of cluster headache.

27 Jun 2011

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

Maternal MS not linked with poor pregnancy or birth outcomes

Canadian researchers have found that maternal multiple sclerosis (MS) is generally not associated with adverse delivery outcomes or risk to their offspring. Full findings now appear in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association.

27 Jun 2011

Some HIV drugs can cause premature ageing

A class of anti-retroviral drugs commonly used to treat HIV, particularly in Africa and low income countries, can cause premature ageing, according to research published today in the journal Nature Genetics. The study shows that the drugs damage DNA in the patient's mitochondria - the 'batteries' which power their cells.

27 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Study traces precursor of deadly esophageal cancers to leftover embryonic cells

The ultimate source of some cancers is embryonic cells. Research published in the June 24th Cell, a Cell Press publication, traces the precursor of deadly esophageal cancers to leftover embryonic cells found in all adults.

24 Jun 2011

New IUPUI facility to focus on urban health issues

A new center at Indiana University-Purdue University Indianapolis has a tall order to fill - improving the quality of life for billions of people.

24 Jun 2011

Scientists analyse factors that influence development of burnout syndrome

Being over-burdened with work, monotony and the perception of lack of recognition can all be catalysts for burnout syndrome. A team of scientists has analysed the factors that influence the development of the three sub-types of this condition - 'frenetic', 'under-challenged' and 'worn out'.

24 Jun 2011

Chronic News and Research

Obama administration plans 'stealth' study of patient access to physicians

Viewpoints: Supreme Court drug decisions; Medicaid's burden; Concierge medicine questioned

Researchers identify how sooty mangabeys survive SIV infection

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

First Edition: June 27, 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Positive results from Stealth's Bendavia Phase I renal impairment study

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Maternal MS not linked with poor pregnancy or birth outcomes

Some HIV drugs can cause premature ageing

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

Study traces precursor of deadly esophageal cancers to leftover embryonic cells

New IUPUI facility to focus on urban health issues

Scientists analyse factors that influence development of burnout syndrome

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News